Warning: file_put_contents(/opt/frankenphp/design.onmedianet.com/storage/proxy/cache/c01b394a7775c621aff4a6e0ef583e1d.html): Failed to open stream: No space left on device in /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php on line 36

Warning: http_response_code(): Cannot set response code - headers already sent (output started at /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php:36) in /opt/frankenphp/design.onmedianet.com/app/src/Models/Response.php on line 17

Warning: Cannot modify header information - headers already sent by (output started at /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php:36) in /opt/frankenphp/design.onmedianet.com/app/src/Models/Response.php on line 20
EGX-A - Wikipedia Jump to content

EGX-A

Add links
From Wikipedia, the free encyclopedia

EGX-A
Clinical data
Other namesEGXA
Drug classSerotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

EGX-A is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders.[1][2][3] It acts as a full agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and produces antidepressant-like effects in rodents.[3] The drug is being developed by atai Life Sciences and EntheogeniX Biosciences.[1][2] As of January 2024, it is in the preclinical research stage of development.[1][2]

See also

[edit]

References

[edit]
  1. ^ a b c "EGX A - AdisInsight". adisinsight.springer.com.
  2. ^ a b c "Delving into the Latest Updates on EGX-A with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
  3. ^ a b Bowen C, Khan T, Perni R, Aron R, Gibbs A, Shin R, et al. (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P362. Discovery of Novel 5-HT2A Receptor Agonists With Psychedelic Drug-Like in Vitro and in Vivo Pharmacological Activity and Therapeutic Potential for Treatment-Resistant Depression". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (275–275). doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
[edit]



Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=EGX-A&oldid=1285002933"